PURPOSE: We investigated the association between prevalence of symptoms and health-related quality of life (HRQOL) in adult survivors of childhood cancer enrolled in the St Jude Lifetime Cohort study. METHODS: Eligibility criteria include childhood malignancy treated at St Jude, survival ≥ 10 years from diagnosis, and current age ≥ 18 years. Study participants were 1,667 survivors (response rate = 65%). Symptoms were self-reported by using a comprehensive health questionnaire and categorized into 12 classes: cardiac; pulmonary; motor/movement; pain in head; pain in back/neck; pain involving sites other than head, neck, and back; sensation abnormalities; disfigurement; learning/memory; anxiety; depression; and somatization. HRQOL was measured by using physical/mental component summary (PCS/MCS) and six domain scores of the Medical Outcomes Study 36-Item Short-Form Health Survey. Multivariable regression analysis was performed to investigate associations between symptom classes and HRQOL. Cumulative prevalence of symptom classes in relation to time from diagnosis was estimated. RESULTS: Pain involving sites other than head, neck and back, and disfigurement represented the most frequent symptom classes, endorsed by 58.7% and 56.3% of survivors, respectively. Approximately 87% of survivors reported multiple symptom classes. Greater symptom prevalence was associated with poorer HRQOL. In multivariable analysis, symptom classes explained up to 60% of the variance in PCS and 56% of the variance in MCS; demographic and clinical variables explained up to 15% of the variance in PCS and 10% of the variance in MCS. Longer time since diagnosis was associated with higher cumulative prevalence in all symptom classes. CONCLUSION: A large proportion of survivors suffered from many symptom classes, which was associated with HRQOL impairment.
PURPOSE: We investigated the association between prevalence of symptoms and health-related quality of life (HRQOL) in adult survivors of childhood cancer enrolled in the St Jude Lifetime Cohort study. METHODS: Eligibility criteria include childhood malignancy treated at St Jude, survival ≥ 10 years from diagnosis, and current age ≥ 18 years. Study participants were 1,667 survivors (response rate = 65%). Symptoms were self-reported by using a comprehensive health questionnaire and categorized into 12 classes: cardiac; pulmonary; motor/movement; pain in head; pain in back/neck; pain involving sites other than head, neck, and back; sensation abnormalities; disfigurement; learning/memory; anxiety; depression; and somatization. HRQOL was measured by using physical/mental component summary (PCS/MCS) and six domain scores of the Medical Outcomes Study 36-Item Short-Form Health Survey. Multivariable regression analysis was performed to investigate associations between symptom classes and HRQOL. Cumulative prevalence of symptom classes in relation to time from diagnosis was estimated. RESULTS:Pain involving sites other than head, neck and back, and disfigurement represented the most frequent symptom classes, endorsed by 58.7% and 56.3% of survivors, respectively. Approximately 87% of survivors reported multiple symptom classes. Greater symptom prevalence was associated with poorer HRQOL. In multivariable analysis, symptom classes explained up to 60% of the variance in PCS and 56% of the variance in MCS; demographic and clinical variables explained up to 15% of the variance in PCS and 10% of the variance in MCS. Longer time since diagnosis was associated with higher cumulative prevalence in all symptom classes. CONCLUSION: A large proportion of survivors suffered from many symptom classes, which was associated with HRQOL impairment.
Authors: L K Zeltzer; E Chen; R Weiss; M D Guo; L L Robison; A T Meadows; J L Mills; H S Nicholson; J Byrne Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: M Apajasalo; H Sintonen; M A Siimes; L Hovi; C Holmberg; H Boyd; A Mäkelä; J Rautonen Journal: Eur J Cancer Date: 1996-07 Impact factor: 9.162
Authors: Cherise B Harrington; Jennifer A Hansen; Michal Moskowitz; Briana L Todd; Michael Feuerstein Journal: Int J Psychiatry Med Date: 2010 Impact factor: 1.210
Authors: Leslie L Robison; Gregory T Armstrong; John D Boice; Eric J Chow; Stella M Davies; Sarah S Donaldson; Daniel M Green; Sue Hammond; Anna T Meadows; Ann C Mertens; John J Mulvihill; Paul C Nathan; Joseph P Neglia; Roger J Packer; Preetha Rajaraman; Charles A Sklar; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness Journal: Lancet Child Adolesc Health Date: 2018-09-01
Authors: Rebecca Williamson Lewis; Karen E Effinger; Karen Wasilewski-Masker; Ann Mertens; Canhua Xiao Journal: Support Care Cancer Date: 2021-07-06 Impact factor: 3.603
Authors: I-Chan Huang; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-23 Impact factor: 4.254
Authors: Hsiu-Ju Yen; Hesham M Eissa; Neel S Bhatt; Sujuan Huang; Matthew J Ehrhardt; Nickhill Bhakta; Kirsten K Ness; Kevin R Krull; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; I-Chan Huang Journal: Blood Date: 2020-05-21 Impact factor: 22.113
Authors: I-Chan Huang; Tara M Brinkman; Larry Mullins; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Psychooncology Date: 2018-06-29 Impact factor: 3.894
Authors: I-Chan Huang; Nickhill Bhakta; Tara M Brinkman; James L Klosky; Kevin R Krull; DeoKumar Srivastava; Melissa M Hudson; Leslie L Robison Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506